The Collaborative Ocular Tuberculosis Study (COTS)-1 : A Multinational Review of 165 Patients with Tubercular Anterior Uveitis
Purpose: The Collaborative Ocular Tuberculosis Study (COTS) Group sought to address the diagnostic uncertainty through retrospective cohort analysis of treatment regimens and therapeutic outcomes for patients with tubercular Anterior Uveitis (TAU) across international centers.Methods: Multicentre retrospective analysis of patients diagnosed with TAU between January 2004 to December 2014 that had a minimum follow-up of 1 year.Results: One hundred and sixty-five patients were included. One hundred and seven subjects received antitubercular therapy (ATT) (n = 107/165; 64.9%) with all the patients receiving topical steroid therapy. Treatment failure was noted in 17 patients (n = 17/165; 10.3%), more frequently described in patients that received ATT (n = 13/107, 12.2%), than those that did not receive ATT (n = 4/58, 6.9%).Conclusion: In this retrospective study, addition of ATT did not have any statistically significant impact on outcome in patients with TAU.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Ocular immunology and inflammation - 28(2020), sup1 vom: 30. Sept., Seite 17-26 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Anti-tubercular therapy |
|---|
| Anmerkungen: |
Date Revised 04.08.2022 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1080/09273948.2020.1761400 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM311782345 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM311782345 | ||
| 003 | DE-627 | ||
| 005 | 20231225143008.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/09273948.2020.1761400 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1039.xml |
| 035 | |a (DE-627)NLM311782345 | ||
| 035 | |a (NLM)32600163 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Agrawal, Rupesh |c MD FCRS |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Collaborative Ocular Tuberculosis Study (COTS)-1 |b A Multinational Review of 165 Patients with Tubercular Anterior Uveitis |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 04.08.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Purpose: The Collaborative Ocular Tuberculosis Study (COTS) Group sought to address the diagnostic uncertainty through retrospective cohort analysis of treatment regimens and therapeutic outcomes for patients with tubercular Anterior Uveitis (TAU) across international centers.Methods: Multicentre retrospective analysis of patients diagnosed with TAU between January 2004 to December 2014 that had a minimum follow-up of 1 year.Results: One hundred and sixty-five patients were included. One hundred and seven subjects received antitubercular therapy (ATT) (n = 107/165; 64.9%) with all the patients receiving topical steroid therapy. Treatment failure was noted in 17 patients (n = 17/165; 10.3%), more frequently described in patients that received ATT (n = 13/107, 12.2%), than those that did not receive ATT (n = 4/58, 6.9%).Conclusion: In this retrospective study, addition of ATT did not have any statistically significant impact on outcome in patients with TAU | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anti-tubercular therapy | |
| 650 | 4 | |a collaborative ocular tuberculosis study (COTS) | |
| 650 | 4 | |a ocular tuberculosis | |
| 650 | 4 | |a tubercular anterior uveitis | |
| 650 | 4 | |a uveitis | |
| 700 | 1 | |a Betzler, Bjorn |c MBBS |e verfasserin |4 aut | |
| 700 | 1 | |a Testi, Ilaria |c MD |e verfasserin |4 aut | |
| 700 | 1 | |a Mahajan, Sarakshi |c MBBS |e verfasserin |4 aut | |
| 700 | 1 | |a Agarwal, Aniruddha |c MS |e verfasserin |4 aut | |
| 700 | 1 | |a Gunasekeran, Dinesh Visva |c MD |e verfasserin |4 aut | |
| 700 | 1 | |a Raje, Dhananjay |c PhD |e verfasserin |4 aut | |
| 700 | 1 | |a Aggarwal, Kanika |c MS |e verfasserin |4 aut | |
| 700 | 1 | |a Murthy, Somasheila I |c DNB |e verfasserin |4 aut | |
| 700 | 1 | |a Westcott, Mark |c FRCSOphth |e verfasserin |4 aut | |
| 700 | 1 | |a Chee, Soon-Phaik |c FRCSEd |e verfasserin |4 aut | |
| 700 | 1 | |a Mccluskey, Peter |c MD |e verfasserin |4 aut | |
| 700 | 1 | |a Ho, Su Ling |c FRCSGlasg |e verfasserin |4 aut | |
| 700 | 1 | |a Teoh, Stephen |c FRCSEd |e verfasserin |4 aut | |
| 700 | 1 | |a Cimino, Luca |c MD |e verfasserin |4 aut | |
| 700 | 1 | |a Biswas, Jyotirmay |c MS |e verfasserin |4 aut | |
| 700 | 1 | |a Narain, Shishir |c MD |e verfasserin |4 aut | |
| 700 | 1 | |a Agarwal, Manisha |c MS |e verfasserin |4 aut | |
| 700 | 1 | |a Mahendradas, Padmamalini |c DNB |e verfasserin |4 aut | |
| 700 | 1 | |a Khairallah, Moncef |c MD |e verfasserin |4 aut | |
| 700 | 1 | |a Jones, Nicholas |c FRCSOphth |e verfasserin |4 aut | |
| 700 | 1 | |a Tugal-Tutkun, Ilknur |c MD |e verfasserin |4 aut | |
| 700 | 1 | |a Babu, Kalpana |c DNB |e verfasserin |4 aut | |
| 700 | 1 | |a Basu, Soumayava |c MS |e verfasserin |4 aut | |
| 700 | 1 | |a Carreño, Ester |c MD |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Richard |c PhD |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Dhibi, Hassan |c MD |e verfasserin |4 aut | |
| 700 | 1 | |a Bodaghi, Bahram |c MD |e verfasserin |4 aut | |
| 700 | 1 | |a Invernizzi, Alessandro |c MD |e verfasserin |4 aut | |
| 700 | 1 | |a Goldstein, Debra A |c MD |e verfasserin |4 aut | |
| 700 | 1 | |a Herbort, Carl P |c MD |e verfasserin |4 aut | |
| 700 | 1 | |a Barisani-Asenbauer, Talin |c PhD |e verfasserin |4 aut | |
| 700 | 1 | |a González-López, Julio J |c PhD |e verfasserin |4 aut | |
| 700 | 1 | |a Androudi, Sofia |c MD |e verfasserin |4 aut | |
| 700 | 1 | |a Bansal, Reema |c MS |e verfasserin |4 aut | |
| 700 | 1 | |a Moharana, Bruttendu |c MS |e verfasserin |4 aut | |
| 700 | 1 | |a Esposti, Simona |c MD |e verfasserin |4 aut | |
| 700 | 1 | |a Tasiopoulou, Anastasia |c MD |e verfasserin |4 aut | |
| 700 | 1 | |a Nadarajah, Sengal |c MD |e verfasserin |4 aut | |
| 700 | 1 | |a Agarwal, Mamta |c DNB |e verfasserin |4 aut | |
| 700 | 1 | |a Abraham, Sharanya |c MD |e verfasserin |4 aut | |
| 700 | 1 | |a Vala, Ruchi |c MD |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Ramandeep |c MS |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Aman |c MD |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Kusum |c PhD |e verfasserin |4 aut | |
| 700 | 1 | |a Zierhut, Manfred |c PhD |e verfasserin |4 aut | |
| 700 | 1 | |a Kon, Onn Min |c MRCP |e verfasserin |4 aut | |
| 700 | 1 | |a Cunningham, Emmett T |c PhD |e verfasserin |4 aut | |
| 700 | 1 | |a Kempen, John H |c PhD |e verfasserin |4 aut | |
| 700 | 1 | |a Nguyen, Quan Dong |c PhD |e verfasserin |4 aut | |
| 700 | 1 | |a Pavesio, Carlos |c FRCSOphth |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Vishali |c MS |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Ocular immunology and inflammation |d 1993 |g 28(2020), sup1 vom: 30. Sept., Seite 17-26 |w (DE-627)NLM091014069 |x 1744-5078 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2020 |g number:sup1 |g day:30 |g month:09 |g pages:17-26 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/09273948.2020.1761400 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2020 |e sup1 |b 30 |c 09 |h 17-26 | ||